SML0744
LDN-27219
≥98% (HPLC)
别名:
2-[(3,4-Dihydro-4-oxo-3,5-diphenylthieno[2,3-d]pyrimidin-2-yl)thio]-acetic acid hydrazide
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 15 mg/mL, clear
storage temp.
−20°C
SMILES string
[s]1c2nc([n]([c](c2c(c1)c4ccccc4)=O)c3ccccc3)SCC(=O)NN
InChI
1S/C20H16N4O2S2/c21-23-16(25)12-28-20-22-18-17(15(11-27-18)13-7-3-1-4-8-13)19(26)24(20)14-9-5-2-6-10-14/h1-11H,12,21H2,(H,23,25)
InChI key
WLBUICQBNZXIDJ-UHFFFAOYSA-N
Biochem/physiol Actions
LDN-27219 is a revesible inhibitor of transglutaminase 2 (TG2) that binds to the GTP binidng site of the enzyme and inhbits activity with and IC50 of 600 nM.
LDN-27219 is a revesible inhibitor of transglutaminase 2 (TG2).
LDN-27219 is a thieno[2,3-d]pyrimidine-4-one-acylhydrazide derivative. Closed conformation of TG2 induced by LDN-27219 can be a potential therapeutic strategy for age-related vascular dysfunction and lowering blood pressure.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable